FDA approves first daily pill to drastically lower cholesterol levels

The FDA has granted approval for Lipfendra, a new once-daily oral medication designed to lower cholesterol. Produced by Merck, this pill is the first of its kind to inhibit the production of PCSK9 proteins, a key regulator in cholesterol management. This development offers an alternative to existing injectable medications that have long been the standard for patients needing more than statins to manage their levels.

Clinical trials demonstrate that Lipfendra reduces levels of low-density lipoprotein cholesterol by more than 56 percent compared to a placebo. By lowering LDL-C, the drug works to reduce the buildup of artery-clogging plaque, which decreases the risk of serious health issues like stroke and heart attack. This new oral option provides a significant shift for patients who currently rely on injections that are often more expensive.

Merck has priced the medication at 10.50 dollars per day. The company expects out-of-pocket costs to remain lower than existing injectable alternatives for most patients, including those with Medicare coverage. This pricing strategy aims to make the treatment accessible to a broader range of individuals who have not reached target cholesterol levels through diet, exercise, or standard statin use.

Beyond traditional pharmacy channels, Merck plans to offer the drug through a discounted cash price program on the federal government prescription drug website. A coupon program will also be available to further reduce costs for eligible patients. This move marks a major change in the landscape of heart health treatments for millions of Americans living with high cholesterol.